AB Science today announced that an abstract report
AB SCIENCE PRESENTS THE RESULTS OF ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMER’S DISEASE AT THE LARGEST CONFERENCE IN THE WORLD FOR RESEARCH ON ALZHEIMER AND DEMENTIA (AAIC 2021)
Paris, 22 July, 2021, 6 p.m. HEC
AB Science SA (Euronext – FR0010557264 – AB) announced today that a summary of the results of its Phase 3 AB09004 Alzheimer’s disease study has been selected for oral presentation at the Alzheimer’s Association (AAIC) Annual International Conference ) (July 26-30, 2021).
AAIC is the largest and most influential international meeting dedicated to the latest research in Alzheimer’s disease and dementia. Last year’s virtual conference attracted over 31,000 registered participants and over 3,000 scientific presentations. This year’s Alzheimer’s Association (AAIC) International Conference is taking place both in person (Denver, USA) and online (hybrid birth model).
Professor Bruno Dubois, director of the Institute for Memory and Alzheimer’s Disease at Pitié-Salpêtrière Hospital in Paris and coordinating investigator of study AB09004, will present key results during the session of the Human Clinical Trials Meeting.
The details of the presentation are as follows:
Title of presentation: Masitinib in mild to moderate Alzheimer’s disease: results of study AB09004
Date and time: Thursday, July 29, 2021, 8:00 a.m. to 9:15 a.m. (MT)
Professor Olivier Hermine, Chairman of the Scientific Committee of AB Science and member of the Académie des Sciences in France, said: “There is an urgent need for innovation drug development approaches which target non-amyloid pathways in the fight against Alzheimer’s disease. Selection of this summary for an oral presentation see you this year Alzheimer Association International conference is an indication of the potential impact of masitinib on the therapeutic landscape for mild to moderate cases Alzheimer’s disease and also the level of interest aroused by this revolutionary approach”.
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, cells important for immunity, by inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of pathologies in oncology, in inflammatory diseases and in certain diseases of the central nervous system. In oncology, because of its immunotherapeutic effect, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and therefore inhibiting the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases and the degeneration of these diseases. .
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKI), a class of targeted proteins whose action is essential in signaling pathways within cells. . Our programs only target diseases with high unmet medical needs, often fatal with short-term survival or rare or refractory to the previous line of treatment.
AB Science has developed an exclusive portfolio of molecules and the Company’s flagship compound, masitinib, has already been registered in veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and is listed on Euronext Paris (ticker: AB).
Further information is available on the AB Science website:
Forward-looking statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on plans, objectives, intentions and expectations regarding financial results, events, operations, future services, development. of products and their potential or future performance.
These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” and other similar terms. Although AB Science believes that these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties which are difficult to predict and generally beyond the control of AB Science and which may imply that the results and actual events differ materially from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include uncertainties related to the development of the Company’s products which may not be successful or to the marketing authorizations granted by the competent authorities or, more generally, any factor that may affect the marketing capacity of the products developed by the Company. AB Science, as well as those developed or identified in public documents published by AB Science. AB Science declines any obligation or commitment to update forward-looking information and statements, subject to applicable regulations, in particular articles 223-1 and following. of the AMF general regulations.
For more information, please contact:
Financial Communication & Press Relations
Media Relations – United States
+1 646 432 0191
Press relations – France
+33 (0) 1 44 71 00 15
CP AAIC2021 preview vEng VF